Search research articles
Contact Us
Filters
Showing results (221-230 of 234) with videos related to
Page
of 24
Sort By:
Oncotarget
|
October 24, 2018
Surrogate endpoints in advanced sarcoma trials: a meta-analysis
Marion Savina, Saskia Litière, Antoine Italiano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 22, 2012
Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era
Philippe A Cassier, Elena Fumagalli, Piotr Rutkowski, et al.
Lancet (London, England)
|
October 19, 2006
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D Demetri, Allan T van Oosterom, Christopher R Garrett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2011
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment
Anne-Joy M de Graan, Sebastiaan F Teunissen, Filip Y F L de Vos, et al.
The Lancet. Oncology
|
May 4, 2010
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study
Rolf D Issels, Lars H Lindner, Jaap Verweij, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2013
CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity
Anne-Joy M de Graan, Laure Elens, Jason A Sprowl, et al.
JAMA Oncology
|
February 17, 2018
Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial
Rolf D Issels, Lars H Lindner, Jaap Verweij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 23, 2012
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors
David Olmos, Roger P A'hern, Silvia Marsoni, et al.
The Lancet. Oncology
|
March 13, 2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Ian Judson, Jaap Verweij, Hans Gelderblom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2012
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure
George D Demetri, Christopher R Garrett, Patrick Schöffski, et al.
Page
of 24
Search research articles
Search
Showing results (221-230 of 234) with videos related to
Sort By:
Page
of 24
Oncotarget
|
October 24, 2018
Surrogate endpoints in advanced sarcoma trials: a meta-analysis
Marion Savina, Saskia Litière, Antoine Italiano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 22, 2012
Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era
Philippe A Cassier, Elena Fumagalli, Piotr Rutkowski, et al.
Lancet (London, England)
|
October 19, 2006
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D Demetri, Allan T van Oosterom, Christopher R Garrett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2011
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment
Anne-Joy M de Graan, Sebastiaan F Teunissen, Filip Y F L de Vos, et al.
The Lancet. Oncology
|
May 4, 2010
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study
Rolf D Issels, Lars H Lindner, Jaap Verweij, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2013
CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity
Anne-Joy M de Graan, Laure Elens, Jason A Sprowl, et al.
JAMA Oncology
|
February 17, 2018
Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial
Rolf D Issels, Lars H Lindner, Jaap Verweij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 23, 2012
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors
David Olmos, Roger P A'hern, Silvia Marsoni, et al.
The Lancet. Oncology
|
March 13, 2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Ian Judson, Jaap Verweij, Hans Gelderblom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2012
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure
George D Demetri, Christopher R Garrett, Patrick Schöffski, et al.
Page
of 24